Legal
Medical Disclaimer
Last reviewed: May 18, 2026
GLPTree provides educational information only. Nothing on this site constitutes medical advice. Always consult a licensed healthcare provider before starting, stopping, or changing any medication or supplement.
Educational Purpose Only
GLPTree is an independent, educational health-information website. All content published on this site — including articles, blog posts, drug guides, clinical trial summaries, dosage information, side-effect descriptions, cost comparisons, and calculator outputs — is created and provided for general educational and informational purposes only.
Our mission is to help people understand published clinical research and publicly available information about GLP-1 receptor agonists, peptide therapies, and metabolic medications. We translate complex clinical trial data into accessible formats so that individuals can have better-informed conversations with their healthcare providers.
No content on this site is intended to, and should not be interpreted to, diagnose any health condition, prescribe any treatment, recommend any specific medication or dosage, substitute for personalized medical assessment, or replace any interaction with a qualified healthcare professional.
No Medical Advice
The information provided on GLPTree does not constitute medical advice, clinical guidance, diagnosis, or treatment recommendation. Even where content references specific drugs, dosing protocols, side effect management strategies, or clinical trial outcomes, this information is provided as educational background — not as direction for your own health decisions.
Health decisions — including starting, stopping, adjusting, or switching any prescription medication — must be made in consultation with a licensed, qualified healthcare professional who knows your full medical history. Never disregard professional medical advice or delay in seeking it because of anything you have read on this site.
If you have questions about your health, a medical condition, or a specific medication, contact your physician, nurse practitioner, pharmacist, or other qualified health provider directly.
No Doctor-Patient Relationship
Your use of GLPTree — regardless of how frequently, how extensively, or in what manner — does not create a doctor-patient relationship, a healthcare provider-patient relationship, a pharmacist-patient relationship, or any other professional-client relationship between you and GLPTree or any of its contributors, editors, or operators.
GLPTree is not a healthcare provider, medical practice, telehealth service, pharmacy, or licensed health service of any kind. No contributor to this site is acting in a professional healthcare capacity when contributing to this site's content.
Calculator Limitations
GLPTree's interactive calculators (including the Weight Loss Projector, Calorie Target Calculator, Protein Needs Calculator, Dose Schedule Calculator, and Cost Estimator) are educational tools — not clinical instruments.
How the calculators work:
- Weight loss projections are derived from mean efficacy data published in major clinical trials (STEP-1 for semaglutide/Wegovy, SURMOUNT-1 for tirzepatide/Mounjaro and Zepbound, SCALE for liraglutide/Saxenda, and others), interpolated using an S-curve model to approximate real-world weight-loss trajectories.
- Calorie targets are calculated using the Mifflin-St Jeor equation, a widely-cited formula for estimating resting metabolic rate.
- Protein recommendations are derived from position statements by recognized nutrition and sports-science bodies (e.g., ISSN).
- Cost estimates are based on publicly reported list prices and manufacturer savings card terms and are subject to change.
What calculator outputs are NOT:
- Not individualized predictions — trial data represents population means; your personal response will differ
- Not prescriptions or dosing recommendations
- Not a basis for self-adjusting medication without clinician guidance
- Not a substitute for metabolic testing, laboratory evaluation, or clinical monitoring
- Not guaranteed to be accurate for your specific situation, health conditions, concurrent medications, or lifestyle
Individual results vary substantially. Use calculator outputs as a starting point for a conversation with your healthcare provider — not as a standalone health decision tool.
FDA-Approval Status of Medications Discussed
GLPTree covers a range of medications and compounds at different stages of regulatory approval. Understanding the difference is critical.
FDA-Approved Medications (as of May 2026)
The following GLP-1 receptor agonists and related medications discussed on this site hold FDA approval for the indicated uses:
| Drug Name | Brand Name(s) | FDA-Approved Indication(s) |
|---|---|---|
| Semaglutide (injectable) | Ozempic®, Wegovy® | Type 2 diabetes (Ozempic); chronic weight management (Wegovy) |
| Semaglutide (oral) | Rybelsus® | Type 2 diabetes |
| Tirzepatide | Mounjaro®, Zepbound® | Type 2 diabetes (Mounjaro); chronic weight management (Zepbound) |
| Liraglutide | Victoza®, Saxenda® | Type 2 diabetes, cardiovascular risk reduction (Victoza); chronic weight management (Saxenda) |
| Dulaglutide | Trulicity® | Type 2 diabetes, cardiovascular risk reduction |
| Exenatide | Byetta®, Bydureon® | Type 2 diabetes |
Investigational & Research Compounds — NOT FDA Approved
The following substances discussed on GLPTree are investigational drugs or research compounds and are NOT approved by the FDA for any therapeutic use as of May 2026:
- Retatrutide (LY3437943) — A triple agonist (GIP/GLP-1/glucagon receptor) in Phase 3 clinical trials by Eli Lilly. Not approved. Not available by prescription. Information about retatrutide on GLPTree is based solely on Phase 1 and Phase 2 published clinical trial data and is provided for educational purposes about the research pipeline.
- CagriSema (cagrilintide + semaglutide) — A combination amylin/GLP-1 agonist in Phase 3 trials by Novo Nordisk. Not approved for commercial use at the time of this writing.
- Survodutide — A GLP-1/glucagon dual agonist in clinical development. Not approved.
- BPC-157 (Body Protection Compound-157) — A synthetic peptide fragment derived from gastric juice protein. Classified as a research chemical. Not approved for human therapeutic use by the FDA. Not permitted for human administration outside of clinical trials.
- AOD-9604 — A modified fragment of human growth hormone. Not FDA approved for obesity or any other indication for human use.
- Tesamorelin — A GHRH analogue. Note: FDA-approved as Egrifta® for a narrow indication (HIV-associated lipodystrophy). Tesamorelin used off-label or obtained outside of this approved indication is not reviewed or endorsed by this site.
- Other research peptides — Various peptides referenced in articles on the GLPTree site are research chemicals with no established human therapeutic approval.
Compounded GLP-1 Medications & Research Peptides — Safety Warning
⚠ Important Safety Notice
Articles on GLPTree (including those covering compounded GLP-1 medications and research peptides) are provided for informational purposes about these compounds and the regulatory landscape surrounding them. This information does NOT constitute guidance, encouragement, or instruction to self-administer any of these substances.
Compounded semaglutide and tirzepatide are subject to evolving FDA oversight. Their production, quality, and purity are regulated under applicable compounding pharmacy law, and standards vary by compounding pharmacy. The FDA has taken enforcement action against certain compounded GLP-1 products. GLPTree does not endorse any specific compounding pharmacy or compounded product.
Research peptides including BPC-157, AOD-9604, and similar compounds are not approved for human use. They are sold legally only for laboratory research purposes. Self-administration carries serious risks including infection, dosing error, contamination, unknown drug interactions, and unknown long-term effects. This site does not endorse, recommend, or facilitate self-administration of research peptides under any circumstances.
If you are interested in investigational therapies, the appropriate pathway is enrollment in a supervised clinical trial. Find open trials at ClinicalTrials.gov.
Emergency Situations
If you are experiencing a medical emergency, call 911 immediately.
- For poisoning or suspected overdose (including from medications or supplements): call Poison Control at 1-800-222-1222 (US) or go to your nearest emergency room.
- For severe allergic reactions, chest pain, difficulty breathing, severe abdominal pain, signs of pancreatitis, or other acute symptoms: call 911 or your local emergency number immediately.
- Do not use this website or any website to self-diagnose or self-treat a medical emergency.
Contact a Doctor Immediately If You Experience:
- Severe or persistent nausea, vomiting, or abdominal pain (possible pancreatitis)
- Severe allergic reaction (rash, swelling, difficulty breathing)
- Vision changes or eye problems
- Signs of low blood sugar (shakiness, confusion, sweating, rapid heartbeat)
- Injection site reactions that worsen or do not resolve
- Any unusual or severe symptoms after starting, stopping, or changing a medication
- Symptoms that concern you — when in doubt, always contact your healthcare provider
Editorial Standards & Content Review
GLPTree is committed to publishing accurate, evidence-based information. Our editorial process is as follows:
- Content is researched and written with reference to primary sources: FDA prescribing information, peer-reviewed journal articles (New England Journal of Medicine, The Lancet, JAMA, and others), and official government health publications.
- Content is reviewed by the GLPTree Clinical Team prior to publication.
- We endeavor to update content when new clinical trial data, FDA decisions, or significant guideline changes occur.
- We cite primary sources wherever possible. We do not accept paid placements or sponsored content. Display advertising (Google AdSense) is clearly labeled and does not influence editorial content.
- Despite our best efforts, health information evolves rapidly. Content may not always reflect the most current clinical guidelines or regulatory status. Always verify information with your healthcare provider and official sources such as FDA.gov and NIH.gov.
To report a factual error or suggest a correction, email info@glptree.com.